# Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

> **NCT01569464** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 150 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Rotigotine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01569464
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569464, "Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01569464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*